Dry powder aerosols based on mucus-penetrating nanocomposite microparticles for pulmonary antibiotics delivery

摘要

Pulmonary antibiotic delivery is increasingly recommended as maintenance therapy to prolong the interval between pulmonary exacerbations and to slow the progression of lung disease in cystic fibrosis (CF) patients with chronic Pseudomonas aeruginosa infection due to its capability to achieve high drug concentrations at the site of infection and to minimize the risk of systemic toxicity and drug resistance. Currently used inhaled formations so far include the nebulization of drugs such as tobramycin which are regarded as inconvenient due to the long administration time and limited portability for chronic drug therapy in daily life of patients. Dry powder formulations of tobramycin have many advantages over nebulizers including faster delivery, easy use, portability, reduced need for cleaning and room temperature storage. However, minimal studies have been completed to control its drug release rate. Besides, the abnormally thick and sticky mucus in respiratory tract of CF patients impairs efficient mucus penetration and limits the range of antibiotics for inhalation.